Cargando…
Heterogeneity in the use of biologics for severe asthma in Europe: a SHARP ERS study
INTRODUCTION: Treatment with biologics for severe asthma is informed by international and national guidelines and defined by national regulating bodies, but how these drugs are used in real-life is unknown. MATERIALS AND METHODS: The European Respiratory Society (ERS) SHARP Clinical Research Collabo...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Respiratory Society
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9589318/ https://www.ncbi.nlm.nih.gov/pubmed/36299366 http://dx.doi.org/10.1183/23120541.00273-2022 |
_version_ | 1784814278601080832 |
---|---|
author | Frix, Anne-Noelle Heaney, Liam G. Dahlén, Barbro Mihaltan, Florin Sergejeva, Svetlana Popović-Grle, Sanja Sedlak, Vratislav Lehtimäki, Lauri Bourdin, Arnaud Korn, Stephanie Zervas, Eleftherios Csoma, Zsuzsanna Lúðvíksdóttir, Dora Butler, Marcus Canonica, Giorgio Walter Grisle, Ineta Bieksiene, Kristina Ten Brinke, Anneke Kuna, Piotr Chaves Loureiro, Claudia Nenasheva, Natalia M. Lazic, Zorica Škrgat, Sabina Ramos-Barbon, David Leuppi, Joerg Gemicioglu, Bilun Bossios, Apostolos Porsbjerg, Celeste M. Bel, Elisabeth H. Djukanovic, Ratko Louis, Renaud |
author_facet | Frix, Anne-Noelle Heaney, Liam G. Dahlén, Barbro Mihaltan, Florin Sergejeva, Svetlana Popović-Grle, Sanja Sedlak, Vratislav Lehtimäki, Lauri Bourdin, Arnaud Korn, Stephanie Zervas, Eleftherios Csoma, Zsuzsanna Lúðvíksdóttir, Dora Butler, Marcus Canonica, Giorgio Walter Grisle, Ineta Bieksiene, Kristina Ten Brinke, Anneke Kuna, Piotr Chaves Loureiro, Claudia Nenasheva, Natalia M. Lazic, Zorica Škrgat, Sabina Ramos-Barbon, David Leuppi, Joerg Gemicioglu, Bilun Bossios, Apostolos Porsbjerg, Celeste M. Bel, Elisabeth H. Djukanovic, Ratko Louis, Renaud |
author_sort | Frix, Anne-Noelle |
collection | PubMed |
description | INTRODUCTION: Treatment with biologics for severe asthma is informed by international and national guidelines and defined by national regulating bodies, but how these drugs are used in real-life is unknown. MATERIALS AND METHODS: The European Respiratory Society (ERS) SHARP Clinical Research Collaboration conducted a three-step survey collecting information on asthma biologics use in Europe. Five geographically distant countries defined the survey questions, focusing on seven end-points: biologics availability and financial issues, prescription and administration modalities, inclusion criteria, continuation criteria, switching biologics, combining biologics and evaluation of corticosteroid toxicity. The survey was then sent to SHARP National Leads of 28 European countries. Finally, selected questions were submitted to a broad group of 263 asthma experts identified by national societies. RESULTS: Availability of biologics varied between countries, with 17 out of 28 countries having all five existing biologics. Authorised prescribers (pulmonologists and other specialists) also differed. In-hospital administration was the preferred deliverance modality. While exacerbation rate was used as an inclusion criterion in all countries, forced expiratory volume in 1 s was used in 46%. Blood eosinophils were an inclusion criterion in all countries for interleukin-5 (IL-5)-targeted and IL-4/IL-13-targeted biologics, with varying thresholds. There were no formally established criteria for continuing biologics. Reduction in exacerbations represented the most important benchmark, followed by improvement in asthma control and quality of life. Only 73% (191 out of 263) of surveyed clinicians assessed their patients for corticosteroid-induced toxicity. CONCLUSION: Our study reveals important heterogeneity in the use of asthma biologics across Europe. To what extent this impacts on clinical outcomes relevant to patients and healthcare services needs further investigation. |
format | Online Article Text |
id | pubmed-9589318 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | European Respiratory Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-95893182022-10-25 Heterogeneity in the use of biologics for severe asthma in Europe: a SHARP ERS study Frix, Anne-Noelle Heaney, Liam G. Dahlén, Barbro Mihaltan, Florin Sergejeva, Svetlana Popović-Grle, Sanja Sedlak, Vratislav Lehtimäki, Lauri Bourdin, Arnaud Korn, Stephanie Zervas, Eleftherios Csoma, Zsuzsanna Lúðvíksdóttir, Dora Butler, Marcus Canonica, Giorgio Walter Grisle, Ineta Bieksiene, Kristina Ten Brinke, Anneke Kuna, Piotr Chaves Loureiro, Claudia Nenasheva, Natalia M. Lazic, Zorica Škrgat, Sabina Ramos-Barbon, David Leuppi, Joerg Gemicioglu, Bilun Bossios, Apostolos Porsbjerg, Celeste M. Bel, Elisabeth H. Djukanovic, Ratko Louis, Renaud ERJ Open Res Original Research Articles INTRODUCTION: Treatment with biologics for severe asthma is informed by international and national guidelines and defined by national regulating bodies, but how these drugs are used in real-life is unknown. MATERIALS AND METHODS: The European Respiratory Society (ERS) SHARP Clinical Research Collaboration conducted a three-step survey collecting information on asthma biologics use in Europe. Five geographically distant countries defined the survey questions, focusing on seven end-points: biologics availability and financial issues, prescription and administration modalities, inclusion criteria, continuation criteria, switching biologics, combining biologics and evaluation of corticosteroid toxicity. The survey was then sent to SHARP National Leads of 28 European countries. Finally, selected questions were submitted to a broad group of 263 asthma experts identified by national societies. RESULTS: Availability of biologics varied between countries, with 17 out of 28 countries having all five existing biologics. Authorised prescribers (pulmonologists and other specialists) also differed. In-hospital administration was the preferred deliverance modality. While exacerbation rate was used as an inclusion criterion in all countries, forced expiratory volume in 1 s was used in 46%. Blood eosinophils were an inclusion criterion in all countries for interleukin-5 (IL-5)-targeted and IL-4/IL-13-targeted biologics, with varying thresholds. There were no formally established criteria for continuing biologics. Reduction in exacerbations represented the most important benchmark, followed by improvement in asthma control and quality of life. Only 73% (191 out of 263) of surveyed clinicians assessed their patients for corticosteroid-induced toxicity. CONCLUSION: Our study reveals important heterogeneity in the use of asthma biologics across Europe. To what extent this impacts on clinical outcomes relevant to patients and healthcare services needs further investigation. European Respiratory Society 2022-10-24 /pmc/articles/PMC9589318/ /pubmed/36299366 http://dx.doi.org/10.1183/23120541.00273-2022 Text en Copyright ©The authors 2022 https://creativecommons.org/licenses/by-nc/4.0/This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions@ersnet.org (mailto:permissions@ersnet.org) |
spellingShingle | Original Research Articles Frix, Anne-Noelle Heaney, Liam G. Dahlén, Barbro Mihaltan, Florin Sergejeva, Svetlana Popović-Grle, Sanja Sedlak, Vratislav Lehtimäki, Lauri Bourdin, Arnaud Korn, Stephanie Zervas, Eleftherios Csoma, Zsuzsanna Lúðvíksdóttir, Dora Butler, Marcus Canonica, Giorgio Walter Grisle, Ineta Bieksiene, Kristina Ten Brinke, Anneke Kuna, Piotr Chaves Loureiro, Claudia Nenasheva, Natalia M. Lazic, Zorica Škrgat, Sabina Ramos-Barbon, David Leuppi, Joerg Gemicioglu, Bilun Bossios, Apostolos Porsbjerg, Celeste M. Bel, Elisabeth H. Djukanovic, Ratko Louis, Renaud Heterogeneity in the use of biologics for severe asthma in Europe: a SHARP ERS study |
title | Heterogeneity in the use of biologics for severe asthma in Europe: a SHARP ERS study |
title_full | Heterogeneity in the use of biologics for severe asthma in Europe: a SHARP ERS study |
title_fullStr | Heterogeneity in the use of biologics for severe asthma in Europe: a SHARP ERS study |
title_full_unstemmed | Heterogeneity in the use of biologics for severe asthma in Europe: a SHARP ERS study |
title_short | Heterogeneity in the use of biologics for severe asthma in Europe: a SHARP ERS study |
title_sort | heterogeneity in the use of biologics for severe asthma in europe: a sharp ers study |
topic | Original Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9589318/ https://www.ncbi.nlm.nih.gov/pubmed/36299366 http://dx.doi.org/10.1183/23120541.00273-2022 |
work_keys_str_mv | AT frixannenoelle heterogeneityintheuseofbiologicsforsevereasthmaineuropeasharpersstudy AT heaneyliamg heterogeneityintheuseofbiologicsforsevereasthmaineuropeasharpersstudy AT dahlenbarbro heterogeneityintheuseofbiologicsforsevereasthmaineuropeasharpersstudy AT mihaltanflorin heterogeneityintheuseofbiologicsforsevereasthmaineuropeasharpersstudy AT sergejevasvetlana heterogeneityintheuseofbiologicsforsevereasthmaineuropeasharpersstudy AT popovicgrlesanja heterogeneityintheuseofbiologicsforsevereasthmaineuropeasharpersstudy AT sedlakvratislav heterogeneityintheuseofbiologicsforsevereasthmaineuropeasharpersstudy AT lehtimakilauri heterogeneityintheuseofbiologicsforsevereasthmaineuropeasharpersstudy AT bourdinarnaud heterogeneityintheuseofbiologicsforsevereasthmaineuropeasharpersstudy AT kornstephanie heterogeneityintheuseofbiologicsforsevereasthmaineuropeasharpersstudy AT zervaseleftherios heterogeneityintheuseofbiologicsforsevereasthmaineuropeasharpersstudy AT csomazsuzsanna heterogeneityintheuseofbiologicsforsevereasthmaineuropeasharpersstudy AT luðviksdottirdora heterogeneityintheuseofbiologicsforsevereasthmaineuropeasharpersstudy AT butlermarcus heterogeneityintheuseofbiologicsforsevereasthmaineuropeasharpersstudy AT canonicagiorgiowalter heterogeneityintheuseofbiologicsforsevereasthmaineuropeasharpersstudy AT grisleineta heterogeneityintheuseofbiologicsforsevereasthmaineuropeasharpersstudy AT bieksienekristina heterogeneityintheuseofbiologicsforsevereasthmaineuropeasharpersstudy AT tenbrinkeanneke heterogeneityintheuseofbiologicsforsevereasthmaineuropeasharpersstudy AT kunapiotr heterogeneityintheuseofbiologicsforsevereasthmaineuropeasharpersstudy AT chavesloureiroclaudia heterogeneityintheuseofbiologicsforsevereasthmaineuropeasharpersstudy AT nenashevanataliam heterogeneityintheuseofbiologicsforsevereasthmaineuropeasharpersstudy AT laziczorica heterogeneityintheuseofbiologicsforsevereasthmaineuropeasharpersstudy AT skrgatsabina heterogeneityintheuseofbiologicsforsevereasthmaineuropeasharpersstudy AT ramosbarbondavid heterogeneityintheuseofbiologicsforsevereasthmaineuropeasharpersstudy AT leuppijoerg heterogeneityintheuseofbiologicsforsevereasthmaineuropeasharpersstudy AT gemicioglubilun heterogeneityintheuseofbiologicsforsevereasthmaineuropeasharpersstudy AT bossiosapostolos heterogeneityintheuseofbiologicsforsevereasthmaineuropeasharpersstudy AT porsbjergcelestem heterogeneityintheuseofbiologicsforsevereasthmaineuropeasharpersstudy AT belelisabethh heterogeneityintheuseofbiologicsforsevereasthmaineuropeasharpersstudy AT djukanovicratko heterogeneityintheuseofbiologicsforsevereasthmaineuropeasharpersstudy AT louisrenaud heterogeneityintheuseofbiologicsforsevereasthmaineuropeasharpersstudy |